Kalaris Therapeutics director files ownership report

Kalaris Therapeutics, Inc. reports that Laurie Keating is a director in an initial insider ownership statement.

Accepted by SEC EDGAR 08/03/2026 - 04:02 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Kalaris Therapeutics, Inc. reports that Laurie Keating is a director in an initial insider ownership statement. The report lists no transactions and shows no securities entries as beneficially owned in the data provided. Remarks reference Exhibit 24.1, described as a Power of Attorney.

Key Figures

Reported transactions: 0

1 metrics

Reported transactions 0 Initial Form 3 beneficial ownership statement for director Laurie Keating

Key Terms

Power of Attorney, Exhibit 24.1

2 terms

Power of Attorney regulatory

"Remarks state: "Exhibit 24.1 - Power of Attorney""

A power of attorney is a legal document that allows one person to make decisions and act on behalf of another person, often in financial or legal matters. It’s like giving someone a trusted helper or agent the authority to handle important tasks if you are unable to do so yourself. This matters to investors because it can impact how their assets are managed or transferred if they become unable to oversee their affairs.

Exhibit 24.1 regulatory

"Remarks state: "Exhibit 24.1 - Power of Attorney""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the KLRS Form 3 filing report for Laurie Keating?

The filing identifies Laurie Keating as a director of Kalaris Therapeutics, Inc. It is an initial insider ownership statement and, in the data provided, shows no transactions or specific securities positions reported for her.

Does the KLRS Form 3 show any share purchases or sales by Laurie Keating?

No. The structured data for this Form 3 shows no reported transactions, with buy and sell counts both at zero. It is an initial ownership report without any recorded purchases, sales, or derivative exercises.

Does Laurie Keating report owning any KLRS shares in this filing?

In this Form 3 data, there are no holding entries reported for Laurie Keating. This means the report does not list any specific Kalaris Therapeutics securities as beneficially owned in the positions section of the statement.

What insider role does Laurie Keating have at Kalaris Therapeutics (KLRS)?

Laurie Keating is coded as a director of Kalaris Therapeutics, Inc. in this insider report. She is not identified as an officer or as a ten percent owner within the roles disclosed in the filing data.

What is Exhibit 24.1 mentioned in the KLRS Form 3 remarks?

The remarks section references “Exhibit 24.1 - Power of Attorney”. This label indicates that an accompanying exhibit identified as 24.1 is a Power of Attorney related to the reporting person’s SEC filings for Kalaris Therapeutics, Inc.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

KEATING LAURIE

(Last) (First) (Middle)

C/O KALARIS THERAPEUTICS, INC.

400 CONNELL DRIVE, SUITE 5500

(Street)

BERKELEY HEIGHTS NEW JERSEY 07922

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
08/01/2026

3. Issuer Name and Ticker or Trading Symbol
Kalaris Therapeutics, Inc. [ KLRS ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24.1 - Power of Attorney

No securities are beneficially owned.

	/s/ Andrew Oxtoby, Attorney-in-Fact	08/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)